Search Aptevo.com
View printer-friendly version
Aptevo Therapeutics Reports Third Quarter 2018 Financial Results
Achieves 132% Increase in IXINITY® Quarterly Net Revenue Year-Over-Year
More than Doubles Year-to-Date IXINITY Net Revenue from
Advances Bispecifics APVO436 and APVO210; On Track to Commence Patient Dosing Q4 2018 and Q1 2019
“Our IXINITY sales performance continues to excel as we focus on ramping up efforts to onboard new patients on IXINITY therapy,” said
In addition to efforts to grow top-line IXINITY net revenue, Aptevo also continued to focus on improving the overall contribution of its IXINITY business, demonstrated by the successful implementation of a new third-party logistics and packaging solution, completed in the third quarter, which is expected to drive significant cost savings and improve operational efficiency.
With U.S. sales growing, Aptevo is implementing new initiatives to further expand the market opportunity for IXINITY in the U.S. and internationally, including: seeking a pediatric label expansion, introducing a more convenient 3000 IU assay for patients, and pursuing ex-US licensing and partnership opportunities.
During the third quarter Aptevo made very good progress advancing its next-generation ADAPTIR platform and is on track to shortly commence dosing of APVO436, its lead, next-generation CD3xCD123 bispecific antibody being evaluated in a Phase 1 clinical study for the treatment of acute myeloid leukemia (AML) and high-grade myelodysplastic syndrome (MDS). The Phase 1/1b open-label clinical study will evaluate escalating doses of APVO436 to determine the safety profile, maximum tolerated dose, and clinical activity of APVO436 in AML and MDS patients.
“We are especially excited to explore the clinical potential of APVO436 as we have made a number of enhancements to our next-generation platform and during the year presented preclinical data at the
Preclinical data presented by Aptevo show that APVO436 is a potent T-cell engager and can stimulate effective T-cell directed tumor killing with reduced cytokine production. Cytokine release syndrome (CRS) is a significant concern with T-cell activating therapies and has been associated with severe complications in clinical trials. Data presented by Aptevo at AACR showed that, compared to an Aptevo-generated version of Macrogenics’ CD123 x CD3 dual-affinity re-targeting (DART) molecule, MGD006, APVO436 induced lower levels of several key T-cell cytokines including IFNg, IL-2, IL-6, and TNFa, suggesting a potential safety advantage with APVO436. Aptevo believes that an improved cytokine release profile could improve the therapeutic index for APVO436 and other next-generation ADAPTIR bispecific candidates.
Aptevo is also progressing plans to advance a second candidate, APVO210, into the clinic in the first quarter of 2019. Preclinical data for APVO210 show that it has a unique mechanism of action as a novel immunosuppressive therapy. Unlike other cytokine-activating autoimmune therapies, APVO210 is designed to modify the effects of IL-10 to retain its immunosuppressive function without producing any undesired proinflammatory effects.
“We are very pleased with the progress we have made this year advancing both APVO210 and APVO436 towards clinical development and look forward to reporting preliminary top-line data from these programs in 2019,” said Dr.
“By streamlining our portfolio we will focus on the discovery and development of higher-value, next-generation ADAPTIR assets that have the greatest potential for value creation,” continued Dr. Stromatt. “Aptevo’s next-generation ADAPTIR technology may potentially overcome many of the challenges encountered with bispecific antibody development. Our next-generation technology incorporates enhancements that enable us to engineer well-characterized molecules with more traditional antibody-like features that potentially have decreased immunogenicity, increased stability, improved potency, extended half-life, and excellent manufacturing characteristics, including the potential for an improved cytokine release profile, evidenced with our APVO436 candidate. Recent clinical data have been presented this year validating prostate specific membrane antigen (PSMA) as a target for prostate cancer, so we are excited to continue development of a PSMA/CD3 ADAPTIR candidate based on our next-generation platform.”
Third Quarter 2018 Highlights
- Achieved 132% increase year-over-year in IXINITY net revenue for third quarter 2018
- Continued to expand the patient base for IXINITY, bringing additional new Hemophilia B patients onto IXINITY therapy during the quarter
- Selected new third-party logistics providers for IXINITY improving supply chain and cost efficiencies
- Increased Aptevo’s available cash by approximately
$18 million ; executed a new term loan agreement with MidCap Financial extending the interest only repayment period toFebruary 1, 2020 with an opportunity for further deferral throughAugust 1, 2020 - Commenced site activation for the APVO436 Phase 1/1b open-label clinical study; anticipate patient dosing to commence shortly
- Furthered plans to commence a Phase 1 clinical study of APVO210 in the first quarter of 2019 in healthy volunteers
- Completed process development activities for ALG.APV-527 and signed an agreement with a CMO for production of Phase 1 clinical trial material; anticipate filing a clinical trial authorization (CTA) in 2019
Third Quarter 2018 Financial Results
Cash Position: Aptevo had cash, cash equivalents, restricted cash, and short-term investments as of
IXINITY Revenue: Product sales of IXINITY increased by
Cost of Product Sales: Cost of product sales increased by
Research and Development Expenses: Research and development expenses increased by
Selling, General and Administrative Expenses: Selling, general and administrative expenses decreased by
Net Income (Loss): Aptevo’s net loss for the three months ended
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts, unaudited)
| September 30, 2018 |
December 31, 2017 |
|||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 28,447 | $ | 7,095 | ||||
| Short-term investments | 9,192 | 73,688 | ||||||
| Accounts receivable | 6,202 | 2,141 | ||||||
| Inventories | 3,969 | 1,028 | ||||||
| Prepaid expenses | 5,195 | 4,022 | ||||||
| Other current assets | 6,990 | 6,710 | ||||||
| Restricted cash | 400 | 400 | ||||||
| Total current assets | 60,395 | 95,084 | ||||||
| Restricted cash, net of current portion | 7,448 | 10,000 | ||||||
| Property and equipment, net | 5,608 | 5,843 | ||||||
| Intangible assets, net | 5,458 | 6,080 | ||||||
| Other assets | 25 | — | ||||||
| Total assets | $ | 78,934 | $ | 117,007 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and other accrued liabilities | $ | 9,808 | $ | 7,350 | ||||
| Accrued compensation | 3,875 | 4,626 | ||||||
| Sales rebates and discounts payable | 936 | 623 | ||||||
| Current portion of long-term debt | — | 3,333 | ||||||
| Other short-term liabilities | 823 | 2,578 | ||||||
| Total current liabilities | 15,442 | 18,510 | ||||||
| Long-term debt, net | 19,143 | 15,728 | ||||||
| Other liabilities | 349 | 734 | ||||||
| Total liabilities | 34,934 | 34,972 | ||||||
| Stockholders' equity: | ||||||||
| Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding | — | — | ||||||
| Common stock: $0.001 par value; 500,000,000 shares authorized; 22,677,270 and 21,605,716 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively | 23 | 22 | ||||||
| Additional paid-in capital | 157,258 | 155,837 | ||||||
| Accumulated other comprehensive loss | (2 | ) | (105 | ) | ||||
| Accumulated deficit | (113,279 | ) | (73,719 | ) | ||||
| Total stockholders' equity | 44,000 | 82,035 | ||||||
| Total liabilities and stockholders' equity | $ | 78,934 | $ | 117,007 | ||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share amounts, unaudited)
| For the Three Months Ended September 30, |
For the Nine Months Ended September 30, |
|||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product sales | $ | 5,824 | $ | 2,506 | $ | 16,721 | $ | 8,131 | ||||||||
| Collaborations | — | 3,666 | — | 3,709 | ||||||||||||
| Total revenues | 5,824 | 6,172 | 16,721 | 11,840 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of product sales | 2,437 | 1,872 | 6,752 | 3,114 | ||||||||||||
| Research and development | 8,574 | 7,175 | 26,486 | 19,835 | ||||||||||||
| Selling, general and administrative | 6,940 | 7,473 | 21,556 | 26,019 | ||||||||||||
| Loss from operations | (12,127 | ) | (10,348 | ) | (38,073 | ) | (37,128 | ) | ||||||||
| Other expense from continuing operations | (474 | ) | (436 | ) | (1,592 | ) | (1,356 | ) | ||||||||
| Loss before income taxes | (12,601 | ) | (10,784 | ) | (39,665 | ) | (38,484 | ) | ||||||||
| Benefit from income taxes | — | 13,768 | — | 15,587 | ||||||||||||
| Net (loss) income from continuing operations | (12,601 | ) | 2,984 | (39,665 | ) | (22,897 | ) | |||||||||
| Discontinued operations (Note 2): | ||||||||||||||||
| Income from discontinued operations, before income taxes | 39 | 56,140 | 104 | 62,706 | ||||||||||||
| Income tax expense | — | (21,257 | ) | — | (23,076 | ) | ||||||||||
| Income from discontinued operations | 39 | 34,883 | 104 | 39,630 | ||||||||||||
| Net (loss) income | $ | (12,562 | ) | $ | 37,867 | $ | (39,561 | ) | $ | 16,733 | ||||||
| Basic net (loss) income per share: | ||||||||||||||||
| Net (loss) income from continuing operations | $ | (0.56 | ) | $ | 0.14 | $ | (1.77 | ) | $ | (1.08 | ) | |||||
| Net income from discontinued operations | $ | — | $ | 1.63 | $ | — | $ | 1.87 | ||||||||
| Net (loss) income per basic share | $ | (0.56 | ) | $ | 1.77 | $ | (1.77 | ) | $ | 0.79 | ||||||
| Weighted-average shares used to compute per share calculations | 22,672,721 | 21,385,381 | 22,431,146 | 21,138,332 | ||||||||||||
| Diluted net (loss) income per share: | ||||||||||||||||
| Net (loss) income from continuing operations | $ | (0.56 | ) | $ | 0.14 | $ | (1.77 | ) | $ | (1.08 | ) | |||||
| Net income from discontinued operations | $ | — | $ | 1.61 | $ | — | $ | 1.87 | ||||||||
| Net (loss) income per diluted share | $ | (0.56 | ) | $ | 1.75 | $ | (1.77 | ) | $ | 0.79 | ||||||
| Weighted-average shares used to compute per share calculations | 22,672,721 | 21,672,269 | 22,431,146 | 21,138,332 | ||||||||||||
About the APVO414 mCRPC Clinical Study
APVO414 is a first-generation bispecific antibody that that was built on Aptevo’s ADAPTIR modular protein therapeutic platform and is designed to simultaneously target prostate specific membrane antigen (PSMA) on prostate cancer cells, and CD3 on T-cells. It functions by redirecting cytotoxic T cell activity towards PSMA-expressing tumor cells.
The Phase 1 clinical study of APVO414 was designed to determine the safety, tolerability and clinical activity of escalating doses of APVO414 delivered by continuous infusion in patients with metastatic castration resistant prostate cancer (mCRPC). A total of 23 patients were treated with continuous infusion, including 3 patients currently enrolled in Cohort 9, where patients are being dosed with 50 mcg/day for 1 week and then dose escalated to 300 mcg/day. To date, no dose limiting toxicities have been reported with continuous infusion. Evidence of pharmacodynamic activity was observed with an increase in activation markers and redistribution of peripheral blood T cells but clinical responses were not obtained at the doses tested. Aptevo has elected to close the study to further enrollment and will continue to monitor patients remaining on therapy.
About the Otlertuzumab PTCL Clinical Study
Otlertuzumab is a first-generation, monospecific antibody targeting CD37 that was built on Aptevo’s ADAPTIR modular protein therapeutic platform. CD37 is a member of the tetraspanin superfamily of molecules and is expressed on the surface of normal and transformed B cells, and also recently discovered to be present on the surface of T-cell lymphomas.
The pilot Phase 2 study of otlertuzumab was designed to evaluate otlertuzumab combined with bendamustine for the treatment of patients with peripheral T cell lymphoma (PTCL). A total of 9 patients were enrolled in the study and the combination of otlertuzumab and bendamustine was well tolerated. Evidence of tumor regression (43% in primary tumor) was observed in one patient, however, there was no evidence of an early response in the remaining patients.
Preliminary immunohistochemistry analysis has revealed that the number of patients with tumors expressing CD37, and the degree of CD37 expression within the tumors, is much lower than that found on tissue panels of PTCL patient samples that were tested prior to the initiation of the pilot study. Based on the uncertainty of CD37 tumor expression and the limited efficacy signal, Aptevo elected to close the study to further enrollment and will continue to monitor patients remaining on therapy.
Otlertuzumab has previously been evaluated in over 250 patients with evidence of clinical activity and a manageable safety profile. Clinical proof-of-concept data from a randomized Phase 2 study of otlertuzumab demonstrated the efficacy and tolerability of otlertuzumab in combination with bendamustine in the treatment of relapsed chronic lymphocytic lymphoma (CLL). In this Phase 2 study there was a significant increase in median progression free survival, from approximately 10 months to 16 months in patients receiving the combination of otlertuzumab and bendamustine.
About
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding potential milestone payments, Aptevo’s outlook, financial performance or financial condition, Aptevo’s technology and related pipeline, collaboration and partnership opportunities, commercial portfolio, milestones, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause Aptevo’s actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo’s business or prospects; challenges in sales and marketing efforts; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevo’s filings with the
Source:
Senior Director, Investor Relations and Corporate Communications
206-859-6628
JurchisonS@apvo.com
Source: Aptevo Therapeutics Inc.